CABA APS: Financial statements 2019
CVR: 39691825
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
CABA APS (CVR 39691825) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -3,125 and a net result of DKK -3,125. Equity in the 2019 report amounted to DKK 43,750. The solvency ratio was 87.5%.
- Gross Profit
- DKK -3,125
- Profit/Loss
- DKK -3,125
- Equity
- DKK 43,750
- Total Assets
- DKK 50,000
- Employees
- 0
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
CABA APS has published its interim report for the period June 18, 2018 – December 31, 2018.
As of April 16, 2019, Søren Luplau-Pagh is registered as director of CABA APS.
As of April 16, 2019, Morten Olesen has stepped down as director of CABA APS.
As of April 16, 2019, Stephan Dr Braun has stepped down as director of CABA APS.
About CABA APS
CABA APS is a Danish company of the type Anpartsselskab based in Fårevejle, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ACBA APS. The management consists of Henrik Nakskov and Søren Luplau-Pagh. The company is owned by Devopharma ApS. In 2025, the company reported a gross profit of DKK -3,125 and a net result of DKK -3,125 compared with DKK -3,125 the year before. Equity in the 2025 report amounted to DKK 25,000.